Pharmafile Logo
Pharmafocus logo
Advanced Search

Johnson & Johnson

Showing 15 posts of 132 posts found.

19916066779_1a281ebca0_b

Johnson & Johnson sued by Washington State for role in the opioid crisis

January 3, 2020
Medical Communications Bernie Sanders, Johnson & Johnson, OxyContin, fentanyl, opioid crisis, opioids

The state of Washington sued pharmaceutical company Johnson & Johnson for deceptive marketing that said their opioids were effective for …

News
jj

J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …

News
johnson_and_johnson_jj_4

J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak

November 7, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Ebola, Janssen, Johnson & Johnson, pharma

Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply …

News

J&J must pay $572 million for fuelling opioid crisis in Oklahoma, judge says

August 27, 2019
Manufacturing and Production J&J, JJ, Johnson & Johnson, Oklahoma, opioid crisis, opioids, pharma

A judge in Oklahoma has said that Johnson & Johnson must pay $572 million for the part it played in …

News

J&J’s ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis

July 26, 2019
Medical Communications, Research and Development Johnson & Johnson, multiple sclerosis, pharma, ponesimod

New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …

News

J&J ‘worse’ than Purdue Pharma expert witness says

June 12, 2019
Research and Development J&J, JJ, Johnson & Johnson, Oklahoma, opioid crisis, phamra

The role Johnson & Johnson played in the opioid crisis was ‘in some ways worse’ than that of Purdue Pharma, …

News

J&J pay $9.9 million to settle surgical mesh implant case

April 23, 2019
Manufacturing and Production . Johnson & Johnson, J&J, JJ, Johnson & Johnson, Litigation, washington

Healthcare conglomerate Johnson & Johnson has agreed to pay $9.9 million to settle a Washington state lawsuit over the firm’s …

News
janssen_latest_logo_on_sign

Janssen closes plant in California, 49 positions axed

April 3, 2019
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, Vacaville, california

Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California. The Johnson & …

News

Indian authorities say J&J’s baby shampoo contains ‘harmful ingredients’

April 1, 2019
Sales and Marketing Cancer, India, J&J, JJ, Johnson & Johnson, Rajasthan, baby shampoo, formaldehyde

Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful …

News
mouse

J&J bows to PETA pressure and drops forced swim tests in mice

March 21, 2019
Medical Communications J&J, JJ, Johnson & Johnson, PETA, animal welfare, pharma

Johnson & Johnson has announced it is to end its practice of forced swim tests on mice, rats and other …

News

J&J to include prices in drug ads on TV

February 8, 2019
Medical Communications J&J, JJ, Johnson & Johnson, Trump, pharma, pricing

US multinational Johnson & Johnson has announced that it will include the price of its medicines in TV commercials for …

News

J&J shares plummet after asbestos cover up allegations emerge

December 17, 2018
Sales and Marketing J&J, JJ, Johnson & Johnson, asbestos, reuters

Shares in American healthcare firm Johnson & Johnson plummeted on Friday after news agency Reuters reported that the New Jersey-based …

News
nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

News
jj_sign_on_wall

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …

News
sandi_peterson

J&J’s second-in-command to retire, alongside executive restructure

June 25, 2018
Medical Communications, Sales and Marketing J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson (pictured) has announced she is to retire from her role and the …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023